Literature DB >> 33246093

Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.

Rui Jiang1, Xiafei Hong1, Yupei Zhao2, Wenming Wu3.   

Abstract

The incidence of pancreatic neuroendocrine neoplasms (PanNENs) has gradually increased. PanNENs comprise two subtypes with different clinical manifestations and molecular mechanisms: functional PanNENs and nonfunctional PanNENs. Excessive hormones and tumor progression severely affect the quality of life of patients or are even life threatening. However, the molecular mechanisms of hormone secretion and tumor progression in PanNENs have not yet been fully elucidated. At present, advancements in sequencing technologies have led to the exploration of new biological markers and an advanced understanding of molecular mechanisms in PanNENs. Multiomics sequencing could reveal differences and similarities in molecular features in different fields. However, sequencing studies of PanNENs are booming and should be summarized to integrate the current findings. In this review, we summarize the current status of multiomics sequencing in PanNENs to further guide its application. We explore mainly advancements in the genome, transcriptome, and DNA methylation fields. In addition, the cell origin of PanNENs, which has been a hot issue in sequencing research, is described in multiple fields.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell origin; Molecular subtype; Multiomics sequencing; Pancreatic neuroendocrine neoplasms

Mesh:

Substances:

Year:  2020        PMID: 33246093     DOI: 10.1016/j.canlet.2020.11.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  1 in total

1.  Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice.

Authors:  Angela Lamarca; Melissa Frizziero; Jorge Barriuso; Zainul Kapacee; Wasat Mansoor; Mairéad G McNamara; Richard A Hubner; Juan W Valle
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.